Could this vaccine stop future coronavirus pandemics?
NCT ID NCT06950177
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-stage trial tests a new vaccine designed to protect against multiple coronaviruses, not just COVID-19. 51 healthy adults aged 18-55 will receive two doses to check safety and immune response. The vaccine uses a protein nanoparticle to target the virus's spike protein, aiming for broader protection.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
CoV-RBD-scNP-001 vaccine with 3M-052-AF adjuvant
What this could lead to
If successful, this could lead to a vaccine that protects against many different coronaviruses, including future pandemic threats.
What could go wrong
This is a very early Phase 1 trial with only 51 healthy adults, so safety and immune response are still unknown. The vaccine may not work as hoped or could cause side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27709, United States